Skip to main content
SpringerLink
Log in

New Endocrine Agents for Breast Cancer

  • Conference paper
Endocrine Therapy of Breast Cancer V

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 29 Accesses

Abstract

The treatment of breast cancer still requires considerable improvement. The introduction of modern endocrine agents such as antioestrogens and aromatase inhibitors has substantially reduced the toxicity associated with major ablative surgical procedures such as adrenalectomy and hypophysectomy and consequently has enhanced the practical applicability of hormone therapy [1]. However, response rate, duration of response and survival in patients with metastatic disease have not been improved [1]. Likewise, the palliative effects of chemotherapy have remained essentially unchanged since the early 70s when adriamycin containing combination regimens were first introduced [2]. In addition, the beneficial effects of endocrine therapy and chemotherapy in patients with early disease, although encouraging, remain restricted to a relatively small fraction of women [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Santen RJ, Manni A, Harvey H and Redmond C: Endocrine treatment of breast cancer in women. Endo Rev 1990 (11):221–265

    Article  Google Scholar 

  2. Henderson IC, Canellos GP: Cancer of the breast. N Engl J Med 1980 (302):17–30

    Article  PubMed  CAS  Google Scholar 

  3. Osborne CK, Coronado EB, Kitten LH, Arteaga Cl, Fuqua SAW, Ramasharma K, Marshall M and Li CH: Insulin-like growth factor-ll (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Molec Endocrinol 1989 (3):1701–1709

    Article  CAS  Google Scholar 

  4. Huff KK, Knabbe C, Lindsey R, Kaufman D, Bronzert D, Lippman ME and Dickson RB: Multihormonal regulation of insulin-like growth factor-l-related protein in MCF-7 human breast cancer cells. Molec Endocrinol 1988 (2):200–208

    Article  CAS  Google Scholar 

  5. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tarn JP, Kudlow JE, Lippman ME and Salomons DS: Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Molec Endocrinol 1988 (2):543–555

    Article  CAS  Google Scholar 

  6. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R and Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987 (48):417–428

    Article  PubMed  CAS  Google Scholar 

  7. Stewart AJ, Johnson MD, May FEB and Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990 (265):21172–21178

    PubMed  CAS  Google Scholar 

  8. Osborne CK, Hamilton B and Nover M: Receptor binding and processing of epidermal growth factor by human breast cancer cells. J Clin Endocrinol Metab 1982 (55):86–93

    Article  CAS  Google Scholar 

  9. Osborne CK, Hamilton B, Titus G and Livingston RB: Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res 1980 (40):2361–2366

    PubMed  CAS  Google Scholar 

  10. Yee D, Paik S, Lebovic R, Favoni R, Cullen K, Lippman ME and Rosen N: Analysis of IGF-I gene expression in malignancy - evidence for a paracrine role in human breat cancer. Molec Endocrinol 1989 (3):509–517

    Article  CAS  Google Scholar 

  11. Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB and Lippman ME: Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA 1987 (84):5763–5767

    Article  PubMed  CAS  Google Scholar 

  12. De Leon DD, Baker B, Wilson DM, Lamson G and Rosenfeld RG: Insulin-like growth factor binding proteins in human breast cancer cells: relationship to hlGFBP-2 and hlGFBP-3. J Clin Endocrinol Metab 1990 (71):530–532

    Article  PubMed  Google Scholar 

  13. De Leon DD, Wilson SM, Baker B, Lamson G, Hintz RL and Rosenfeld RG: Characterization of insulin-like growth factor binding proteins from human breast cancer cells. Molec Endocrinol 1989 (3):567–574

    Article  Google Scholar 

  14. Kim I, Manni A, Lynch J and Hammond JM: Identification and regulation of insulin-like growth factor binding proteins produced by hormone-dependent and -independent human breast cancer cell lines. Molec Cell Endocrinol 1991 (780):71–78

    Article  Google Scholar 

  15. Elgin RG, Busby WH Jr and Clemmons DR: An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 1987 (84):3254–3258

    Article  PubMed  CAS  Google Scholar 

  16. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke BM and Bierich JR: Insulin-like growth factor I (IGF-l)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 1989 (125):766–772

    Article  PubMed  CAS  Google Scholar 

  17. Thomas T, Kiang DT: Structural alterations and stabilization of rabbit uterine estrogen receptors by natural polyamines. Cancer Res 1987 (47):1799–1804

    PubMed  CAS  Google Scholar 

  18. Thomas T, Kiang DT: Modulation of the binding of progesterone receptor to DNA by polyamines. Cancer Res 1988 (48):1217–1222

    PubMed  CAS  Google Scholar 

  19. Manni A, Wright C, Feil P, Baranao L, Demers L, Garcia M and Rochefort H: Autocrine stimulation by estradiol-regulated growth factors of rat hormone-responsive mammary cancer: interaction with the polyamine pathway. Cancer Res 1986 (46):1594–1598

    PubMed  CAS  Google Scholar 

  20. Manni A, Wright C, Hsu C-J and Hammond JM: Polyamines and autocrine control of tumor growth by prolactin in experimental breast cancer in culture. Endocrinology 1986 (119):2033–2037

    Article  PubMed  CAS  Google Scholar 

  21. Glikman PL, Manni A, Bartholomew M and Demers L: Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cell lines in culture. J Steroid Biochem Molec Biol 1990 (37):1–10

    Article  PubMed  CAS  Google Scholar 

  22. Kim I, Manni A, Lynch J and Demers L: Polyamine involvement in the secretion and action of TGF-alpha in hormone sensitive human breast cancer cells in culture. Breast Cancer Res Treat 1991 (18):83–91

    Article  PubMed  CAS  Google Scholar 

  23. Manni A, Wright C, Luk GD, Davis G and Demers L: Role of polyamines in the synthesis of estradiol-regulated growth factors in rat mammary cancer in culture. Breast Cancer Res Treat 1987 (9):45–51

    Article  PubMed  CAS  Google Scholar 

  24. Manni A, Badger B, Wright C, Ahman SR, Santner SJ and Luk G: Role of polyamines in the synthesis of prolactin-regulated growth factors by experimental breast cancer in culture. Breast Cancer Res Treat 1987 (10):191–196

    Article  PubMed  CAS  Google Scholar 

  25. Cohen FJ, Manni A, Glikman P, Bartholomew M and Demers L: Interactions between growth factor secretion and polyamines in MCF-7 breast cancer cells. Eur J Cancer 1990 (26):255–273

    Google Scholar 

  26. Katz MD and Erstad BL: Octreotide, a new somatostatin analogue. Clin Pharm 1989 (8):255–273

    PubMed  CAS  Google Scholar 

  27. Gorden P, Comi RJ, Maton PN and Go VLW: Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Int Med 1989 (110):35–50

    PubMed  CAS  Google Scholar 

  28. Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA and Bartholomew M: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 1989 (14):289–298

    Article  PubMed  CAS  Google Scholar 

  29. Chirlanda G, Ucciolo L, Perri F, Altomonte L, Bertoi A, Manna R, Frati L and Greco AU: Epidermal growth factor, somatostatm and psoriasis. Lancet 1983 (i):65

    Article  Google Scholar 

  30. Viguerie N, Tahiri-Jouti N, Ayral AM, Cambillau C, Scemama JL, Bastie MJ, Knuhtsen S, Esteve JP, Pradayrol L, Susini C and Vaysse N: Direct inhibitory effects of a somatostatin analog, SMS 201–995, on AR4–2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein independent mechanism. Endocrinology 1989 (124):1017–1025

    Article  PubMed  CAS  Google Scholar 

  31. Mascardo RN and Sherline P: Somatostatin inhibits rapid intrasomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 1982 (111):1394–1396

    Article  PubMed  CAS  Google Scholar 

  32. Setyono-Han B, Henkelman MS, Foekens JA and Klihn JGM: Direct inhibitory effects of somatostatin (analogues) on thre growth of human breast cancer cells. Cancer Res 1987 (47): 1566–1570

    PubMed  Google Scholar 

  33. Reubi JC, Waser B, Foekens JA, Klihn JGM, Lamberts SWJ and Laissue J: Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990 (46):416–420

    Article  PubMed  CAS  Google Scholar 

  34. Schally AV, Coy DH and Meyers CA: Hypothalamic regulatory hormones. Ann Rev Biochem 1978 (47):89–128

    Article  PubMed  CAS  Google Scholar 

  35. Schally AV and Redding TW: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 1987 (84):7275–7279

    Article  PubMed  CAS  Google Scholar 

  36. Schally AV, Cai RZ, Torres-Aleman I, Redding TW, Szoke B, Fu D, Hierowski MT, Colaluca J and Konturek S: Endocrine, gastrointestinal and antitumor activity of somatostatin analogs. In: Moody TW (ed) Neural and Endocrine Peptides and Receptors. Plenum Publ Corp, New York 1986 pp 73–83

    Google Scholar 

  37. Schally AV, Redding TW, Cai RZ, Paz Jl, Ben-David M and Comaru-Schally AM: Somatostatin analogs in the treatment of various experimental tumors. In: Klijn JGM (ed) International Symposium on Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (anti)Steroidal Agents. Raven Press, New York 1987 pp 431–440

    Google Scholar 

  38. Schally AV, Redding TW, Paz-Bouza Jl, Comaru-Schally AM and Mathe G: Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents. In: Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds) Prostate Cancer, Part A. Alan R Liss, New York 1987 pp 173–197

    Google Scholar 

  39. Manni A, Wright C, Davis G, Glenn J, Joehl R and Feil P: Promotion by prolactin of the growth of human breast neoplasms cultured in vitro on the soft agar clonogenic assay. Cancer Res 1986 (46):1669–1672

    PubMed  CAS  Google Scholar 

  40. Malarkey WB, Kennedy M, Allred LE and Milo G: Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab 1983 (56):673–677

    Article  PubMed  CAS  Google Scholar 

  41. DeSouza I, Morgan L, Lewis UJ, Raggatt PR, Salih H and Hobbs JR: Growth-hormone dependence among human breast cancers. The Lancet 1974 (2):182–184

    Article  CAS  Google Scholar 

  42. Vennin PH, Peyrat JP, Bonneterre J, Louchez MM, Harris AG and Demaile A: Effect of the long-acting somatostatin analogue SMS 201–995 (Sandostatin) in advanced breast cancer. Anticancer Res 1989 (9):153–156

    PubMed  CAS  Google Scholar 

  43. Pollak MN, Polychronakos C and Guyda H: Somatostatin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989 (9):889–892

    PubMed  CAS  Google Scholar 

  44. Stolfi R, Parisi AM, Natoli C and lacobelli S: Advanced breast cancer: response to somatostatin. Anticancer Res 1990 (10):203–204

    PubMed  CAS  Google Scholar 

  45. Kvols KL, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J and Hahn RJ: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986 (315):663–666

    Article  PubMed  CAS  Google Scholar 

  46. Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O’Connell MJ and Hahn RG: Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201–995). Ann Int Med 1987 (107):162–168

    PubMed  CAS  Google Scholar 

  47. Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ and Owen OE: Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201–995. N Engl J Med 1986 (314):1686–1689

    Article  PubMed  CAS  Google Scholar 

  48. Maton PN, O’Dorisio TM, Howe BA, McArthur KE, Howard JH, Cherner JA, Malarkey TB, Collen MJ, Gardner JD and Jensen RT: Effect of a long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera. N Engl J Med 1985 (312):17–21

    Article  PubMed  CAS  Google Scholar 

  49. Ho KY, Weissberger AJ, Marbach P and Lazarus L: Therapeutic efficacy of the somatostatin analog SMS 201–995 (octroitide) in acromegaly: effects of dose and frequency and long-term safety. Ann Int Med 1990 (112):173–181

    PubMed  CAS  Google Scholar 

  50. Arteaga CL and Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989 (49):6237–6241

    PubMed  CAS  Google Scholar 

  51. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Menselsohn J and Dickson RB: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Molec Endocrinol 1989 (3):1830–1838

    Article  CAS  Google Scholar 

  52. Ahmed SR, Badger B, Wright C and Manni A: Role of transforming growth factor alpha in basal and hormone stimulated growth by estradiol, prolactin and progesterone in human and rat mammary tumor cells: studies using TGF-alpha and EGF receptor antibodies. J Steroid Biochem Molec Biol 1991 (38):687–693

    Article  PubMed  CAS  Google Scholar 

  53. Glickman PL, Manni A, Bartholomew M and Demers L: Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cells in culture. J Steroid Biochem Molec Biol 1990 (37): 1–10

    Article  Google Scholar 

  54. Masui H, Kawamoto T, Sato JD, Wolf B, Sato GH and Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-EGF receptor monoclonal antibodies. Cancer Res 1984 (44):1002–1007

    PubMed  CAS  Google Scholar 

  55. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Full FC, Allred DC and Osborne CK: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989 (84):1418–1423

    Article  PubMed  CAS  Google Scholar 

  56. Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents. J Steroid Biochem Molec Biol 1990 (37):889–892

    Article  PubMed  CAS  Google Scholar 

  57. Manni A and Wright C: Polyamines as mediators of estrogen action on the growth of experimental breast cancer in rats. JNCI 1984 (73):511–514

    PubMed  CAS  Google Scholar 

  58. Manni A and Wright C: Polyamines as mediators of the effect of prolactin and growth hormone on the growth of N-nitroso-N-methylurea-induced rat mammary tumor culture in vitro in soft agar. JNCI 1985 (74):941–944

    PubMed  CAS  Google Scholar 

  59. Lima G and Shiu RPC: Role of polyamines in estradiol-induced growth of human breast cancer cells. Cancer Res 1985 (45):2466–2470

    PubMed  CAS  Google Scholar 

  60. Manni A, Badger B, Lynch J and Demers L: Selectivity of polyamine involvement in hormone action on normal and neoplastic target tissues of the rat. Breast Cancer Res Treat 1990 (17):187–196

    Article  Google Scholar 

  61. Manni A, Lancaster S, English H, Badger B, Lynch J and Demers L: Kinetic and morhopmetric response of heterogeneous populations of NMU-induced rat mammary tumor cells to hormone and antipolyamine therapy in vivo. Breast Cancer Res Treat 1990 (17):179–186

    Article  Google Scholar 

  62. Carbone PP, Love RR, Carey P, Tutsch K, Verma AK, Wilding G and Silmore-Cunningham D: Phase I and pharmacokinetics study of difluoromethyl-ornithine (DFMO), a potential chemopreventive. Proc of the 82nd Mtg of the Am Assoc Cancer Res, May 15–18, 1991, Houston, Texas, (abstr 1209)

    Google Scholar 

  63. Dowsett M: Novel approaches to the endocrine therapy of breast cancer. Eur J Cancer 1990 (26):989–992

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, The Pennsylvania State University, The Milton S. Hershey Medical Center, Hershey, PA, 17033, USA

    Andrea Manni

Authors
  1. Andrea Manni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Ospedale Civico, via Tesserete 46, 6900, Lugano, Switzerland

    A. Goldhirsch

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Manni, A. (1992). New Endocrine Agents for Breast Cancer. In: Goldhirsch, A. (eds) Endocrine Therapy of Breast Cancer V. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77662-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77662-5_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77664-9

  • Online ISBN: 978-3-642-77662-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation